New-onset atrial fibrillation in the critically ill patient: Where are we?

Translated title of the contribution: New-onset atrial fibrillation in the critically ill patient: Where are we?

Mario Andres Hernandez-Sómerson, Omar Bernal-Ramirez, Juan Camilo Jiménez-Palomino, Samuel Rodriguez-Urueña, Fernando Montoya Agudelo, Alberto Gonzalez-Robles, Handerson Rafael Osma-Charris, Camilo Escobar-Castaño

Research output: Contribution to journalShort surveypeer-review

Abstract

New-onset atrial fibrillation in the critically ill patient has different risk factors, clinical outcomes, and treatments than in the outpatient setting. Its incidence in general intensive care is about 4.5% to 15%, and is often a transient event, as well as being considered a marker of the severity and a risk factor for morbidity and mortality. However, few clinical studies support the interventions. Treatment of the triggering cause is its first step of management, an strategy of control the heart rate must be the initial goal, and the use of electrical or pharmacological cardioversion should be determined by the stability of the patient. Finally, an appropriate estimate of the risk of bleeding and stroke should define the start of anticoagulation.

Translated title of the contributionNew-onset atrial fibrillation in the critically ill patient: Where are we?
Original languageEnglish
Pages (from-to)22-30
Number of pages9
JournalActa Colombiana de Cuidado Intensivo
Volume18
Issue number1
DOIs
StatePublished - 1 Jan 2018

Keywords

  • Antiarrhythmic
  • Anticoagulation
  • Atrial fibrillation
  • Critical care
  • Electrical cardioversion

Fingerprint

Dive into the research topics of 'New-onset atrial fibrillation in the critically ill patient: Where are we?'. Together they form a unique fingerprint.

Cite this